Date and Time
September 22, 2010
1:30 PM - 3:00 PM

Availability
Open to the public
No RSVP required

Please note: All research in progress seminars are off-the-record. Any information about methodology and/or results are embargoed until publication.

Antiretroviral therapy (ART) for HIV is evolving quickly. Many new agents have been introduced in the past 5 years. Concurrently however, observational data suggests that some older agents are associated with an increased risk of cardiovascular disease, a major concern as life expectancy in treated patients with HIV approaches or exceeds 30 years. We will discuss work from our Challenge Grant on the comparative effectiveness of HIV antiretroviral agents. We will present preliminary results of our systematic review of the risk of CV disease from ART, and our cost-effectiveness analysis of new and expensive antiretroviral drugs in patients who have multidrug resistant HIV.